FDA is considering when it should deny approval or withdraw approval of opioids that lack abuse-deterrent features and sought input on the issue during a two-day public meeting.
The Oct. 30-31 meeting on the development and regulation of abuse-deterrent opioid medications focused on manufacturing and regulatory challenges and...